Keystone Symposia on Atherosclerosis Lessons Learned and Concepts Challenged

Event Information

Meeting Type: Physical
Meeting Website:
Dates: February 4 - 8, 2018
Location: Taos, New Mexico , United States
Intended Audience: Basic Scientist, Clinical Scientist, Early Career, In Training, Media, Physician or Advanced Practice Professional
Sponsor: Keystone Symposia on Molecular and Cellular Biology
Purpose: Education, Scientific
Number of CME Credits Offered: None

Topics: Adipose Tissue Appetite and Obestity, Aging, Cardiovascular Endocrinology, Diabetes Mellitus and Glucose Metabolism, Endocrine Genetics, Lipids, Nutrition, Thyroid

Description: Abstract Deadline: Nov 7, 2017
Discounted Registration Deadline: Dec 7, 2017
Atherosclerosis is a chronic, systemic disease process whereby fatty deposits, inflammation and fibrosis accumulate in arterial vessel walls. Organ systems, including heart, brain, kidneys, as well as extremities, can be damaged, leading to atherosclerosis-driven clinical outcomes. According to the American Heart Association, 15.5 million Americans have coronary heart disease, of which 7.6 million experienced myocardial infarction. These statistics are reflective of global incidence. Treatment of atherosclerosis often begins with robust cholesterol-lowering treatments, yet many patients continue to experience cardiovascular events. Recent attempts to provide cardiovascular protection to such patients have included anti-inflammatory and HDL-raising therapeutic approaches that have yielded little benefit. Building knowledge of atherosclerosis disease etiology, defining unique attributes of patient differences as simple as sex or genetic inheritance, and using technology to identify patients with early disease is foundational for the scientific community to develop urgently needed therapeutics. The current concept of acute coronary syndrome (“the vulnerable plaque”) and widely applied animal models are debated because clinical presentation, underlying pathology and pathogenetic mechanisms are subject to change due to improved medical treatment. The goals of this meeting are to: 1) Challenge current dogma of atherosclerosis etiology and explore intra-organ cross-talk that may underlie disease evolution; 2) Consider emerging risk factors and their origins as intervention targets; and 3) Explore cutting-edge technologies to discover new therapeutic targets and approaches for drug development. By bringing together scientists from preclinical to clinical settings and from industry to academic institutions, this conference will nurture discussions to translate breakthrough discoveries into therapeutics.

Event Contact

Name: Attendee Services
Phone: 970.262.1230
Fax: 970.262.1525